MSD to create 200 new jobs in Carlow, Cork and Tipperary
Expansion reflects critical role of MSD’s Irish sites in wider global network.
MSD will create 200 new jobs across three of its Irish manufacturing sites by the end of 2016. Due to continued growth and an increase in the supply of products to the global market from Ireland, MSD is recruiting experienced professionals for positions based at MSD’s locations in Carlow, Cork and Tipperary.
The new roles span Operations, Quality, Engineering, Supply Chain, and Commercial Operations.
Ger Carmody, Associate Vice President, and Site Lead at MSD in Ballydine, Tipperary, said: “Today’s announcement reflects the critical role MSD’s Irish sites play in our wider global manufacturing network. Those taking up these new roles will be at the cutting edge of healthcare innovation and will play a key role in delivering MSD’s overall ambition to preserve and improve human life. Our state-of-the-art facilities in Carlow, Cork and Tipperary are leading the way in the development of new medicines, including MSD’s new treatments for cancer and hepatitis C, which are being manufactured in Ireland for the world market. Today, our Irish sites are involved in the production of over 60% of MSD’s global top 20 products.”
MSD in Carlow, the company’s only standalone vaccine and biologics facility outside the US, is creating 110 new roles spanning production, engineering and quality control. MSD in Brinny, Co. Cork, which specialises in the fermentation and sterile filling of biotech products, is seeking 50 new hires in manufacturing, quality, technology, engineering and environmental & safety. Finally, MSD in Ballydine, Co. Tipperary, which is involved in the R&D, formulation and manufacture of active pharmaceutical ingredients, will recruit 40 new employees, including process and chemical engineers and organic chemists by year end.
Recognised as Ireland’s Pharma Company and Biopharma Company of the Year in 2015, MSD already employs over 2,000 people across five sites in Ireland – in Dublin, Carlow, Cork, Tipperary and Wicklow. Its extensive Irish operations, encompassing manufacturing, commercial, global financial services and marketing facilities, had a turnover of €3 billion in 2014. MSD has a strong legacy in Ireland that stretches back over the last 50 years, and in that time, the company has invested over $2.5 billion in expanding and developing its facilities here. The company provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immunology, oncology, infectious diseases, women’s health and anaesthesia.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance